Results 111 to 120 of about 2,320,535 (398)

Preclinical common data elements for general pharmacological studies (pharmacokinetic sample collection, tolerability, and drug administration). A report of the TASK3‐WG1A General Pharmacology Working Group of the ILAE/AES Joint Translational Task Force

Epilepsia Open
Growing concerns over rigor and reproducibility of preclinical studies, including consistency across laboratories and translation to clinical populations, have triggered efforts to harmonize methodologies.
Lisa Coles, Patrick A. Forcelli, Karine Leclercq, Anna‐Maria Katsarou, Brian D. Klein, Heidrun Potschka, Rudiger Koehling, Lauren Harte‐Hargrove, Aristea S. Galanopoulou, Cameron S. Metcalf   +9 more
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

Pharmacological Reviews, 2017
The study of botulinum neurotoxins (BoNT) is rapidly progressing in many aspects. Novel BoNTs are being discovered owing to next generation sequencing, but their biologic and pharmacological properties remain largely unknown.
M. Pirazzini, O. Rossetto, R. Eleopra, C. Montecucco   +3 more
semanticscholar   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Melatonin: Pharmacology, Functions and Therapeutic Benefits

Current Neuropharmacology, 2017
: Background: Melatonin synchronizes central but also peripheral oscillators (fetal adrenal gland, pancreas, liver, kidney, heart, lung, fat, gut, etc.), allowing temporal organization of biological functions through circadian rhythms (24-hour cycles) in
S. Tordjman, S. Chokron, R. Delorme, Annaëlle Charrier, É. Bellissant, N. Jaafari, C. Fougerou   +6 more
semanticscholar   +1 more source

Comprehensive Review of Ustekinumab Utilization in Inflammatory Bowel Diseases: Insights from the ClinicalTrials.gov Registry

International Journal of General Medicine, 2023
Nasser M Alorfi,1 Mansour M Alourfi,2,3 Ghfran Abdulrahman Bokhari,3 Abdullah Alkhattabi,3 Nihal Abdalla Ibrahim,4 Abdulmalik Mohammed Alsabban,5 Mohammad J Almatrafi,5 Yaser Abdulaziz Zakri,5 Abdullah Jasem Almahmoud,6 Khalid Mohammed A Al-ghamdi,6 ...
Alorfi NM, Alourfi MM, Bokhari GA, Alkhattabi A, Ibrahim NA, Alsabban AM, Almatrafi MJ, Zakri YA, Almahmoud AJ, Al-ghamdi KMA, Alsharif SN   +10 more
doaj  

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2

International Journal of Molecular Sciences, 2018
Vascular endothelial growth factor-A (VEGF-A) is a key mediator of angiogenesis, signalling via the class IV tyrosine kinase receptor family of VEGF Receptors (VEGFRs).
C. Peach, V. Mignone, M. Arruda, Diana C. Alcobia, S. Hill, L. Kilpatrick, J. Woolard   +6 more
semanticscholar   +1 more source

Statistics in Pharmacology [PDF]

British Journal of Pharmacology, 2007
Statistics is an important tool in pharmacological research that is used to summarize (descriptive statistics) experimental data in terms of central tendency (mean or median) and variance (standard deviation, standard error of the mean, confidence interval or range) but more importantly it enables us to conduct hypothesis testing. This is of particular
openaire   +3 more sources

Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen

Molecular Therapy: Nucleic Acids
Angiotensinogen (AGT) is the precursor of angiotensin II, a potent vasopressor in the renin-angiotensin-aldosterone system. Small interfering RNAs (siRNAs) targeting hepatic AGT can lower blood pressure in hypertension patients by reducing AGT levels ...
Ze-Ao Huang, Guang-Shen Ji, Shuo Yang, Yang Yang, Yu-Cheng Wu, Zhi-Kang Tian, Geng-Shen Song   +6 more
doaj   +1 more source